Status:

WITHDRAWN

The Inova Type 2 Diabetes Mellitus Study

Lead Sponsor:

Inova Health Care Services

Conditions:

Diabetes, Type 2

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

The purpose of this study is to compare the safety and effectiveness of the two different basal insulins commonly used for basal blood sugar control in the treatment of type 2 diabetes mellitus in pat...

Detailed Description

This is a randomized, open label trial comparing effectiveness of insulin glargine and insulin NPH in a basal plus correctional regimen. Patients will be randomized to either an intervention (NPH) or ...

Eligibility Criteria

Inclusion

  • Adult patients ages18-75 admitted to a general medicine or surgical Department of Medicine hospitalist services.
  • A known history of T2DM, receiving either diet alone, low dose insulin (≤0.4 units/kg/day), OADs, GLP1 analogs, or in any combination of OADs, GLP1 analogs and low dose insulin (≤0.4 units/kg/day).
  • Subjects must have a BG \>140 mg/dL and ≤240 mg/dL before randomization without laboratory evidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic syndrome (bicarbonate \<18 mEq/L, pH \<7.30, or positive serum or urinary ketones, BG \>240 mg/dL).

Exclusion

  • Patients with a diagnosis of type 1 diabetes mellitus.
  • Patients using nutritional bolus insulin at home.
  • Patients with increased blood glucose concentration, but without a known history of diabetes.
  • Patients with a history of diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic syndrome, or ketonuria.
  • Patients admitted to or expected to require admission to any intensive care unit (ICU) or intermediate care unit (IMC).
  • Patients who are receiving or are anticipated to receive enteral or parenteral nutrition.
  • Patients admitted for cardiac surgery.
  • Patients receiving continuous insulin infusion.
  • Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, or impaired renal function (creatinine ≥ 3.5 mg/dL).
  • Persons with decisional incapacity (mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study).
  • Female subjects who are pregnant or immediately (same hospitalization) post partum at time of enrollment into the study.
  • Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.

Key Trial Info

Start Date :

April 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2016

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT02222623

Start Date

April 1 2015

End Date

May 1 2016

Last Update

August 5 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Inova Fairfax Hospital

Falls Church, Virginia, United States, 22042